FGFR mutations are frequent in human cancers (16, 22), with the highest prevalence in NSCLC (FGFR1 range 0–18%) (17, 20, 23, 62), endometrial carcinoma (FGFR2, range 0–9%) (35, 63), bladder carcinoma (FGFR3, range 8.5–26%) (53, 64), and rhabdomyosarcoma (FGFR4 7.5%) (65) (Table 1 and Supplemental Table S2). Here, FGFR1 is linked to non-small cell lung carcinoma.